重磅品种延保五年市场独占!罗氏、荣昌等创新药专利补偿兑现

医药经济报
20 Jun

近日,荣昌生物公告其核心产品泰它西普获得国家知识产权局授予的专利权期限补偿,补偿天数为1827天,使得该药的专利权期满终止日从2027年6月15日延长到2032年6月15日。这是我国药品专利权期限补偿制度实施以来,继新疆华春生物的中药1.1类创新药参葛补肾胶囊、罗氏的抗PD-L1抑制剂阿替利珠单抗后,又一个获得“顶格补偿”的案例。业界普遍认为,此次获得额外五年的市场保护,将显著提升泰它西普在国内...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10